$63.02
0.931.5%
Last update: Oct 29, 7:33 AM
PTC Therapeutics Inc (PTCT) Stock Price, Quote, News & History
PTCTNASDAQ
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.
You can purchase shares of PTC Therapeutics (NASDAQ:PTCT) through any online brokerage.
Other companies in PTC Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
PTC Therapeutics has a consensus price target of $84.67.
The stock price for PTC Therapeutics (NASDAQ: PTCT) is $63.79 last updated October 29, 2026 at 7:33 AM EDT.
There are no upcoming dividends for PTC Therapeutics.
PTC Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for PTC Therapeutics.
PTC Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that...
